The Spanish Association for the Discovery of New Antibiotics in Spain (AD-ES) is a non-profit organization that brings together experts in different disciplines and scientific areas interested in the discovery and development of new antibiotics necessary for the fight against multidrug-resistant bacteria.
Infectious diseases have been and will continue to be a threat to humanity. Antibiotic resistance is one of the main global health challenges that humanity will have to face during the 21st century. Political leaders and those responsible for large private entities must approach the future with a visionary attitude, capable of measuring the consequences of this challenge and taking the necessary measures to mitigate its effects. To combat this threat, urgent and coordinated action must be taken by the government, industry, the scientific community and society as a whole.
Launched in June 2015, the BEAM Alliance (Biotech companies from Europe innovating in Anti-Microbial resistance research) represents over 60 small and medium-sized European companies involved in developing innovative products and kits to tackle antimicrobial resistance (AMR), including small molecule antibiotics, biologics, products with a prophylaxis indication, microbiome-based and phage-based therapies, immune targeting therapies, anti-biofilm agents and in vitro diagnostic devices.
BEAM collaborates with the existing community of stakeholders dedicated to implementing tangible strategies. BEAM gives its members a unique voice to propose and support policies and incentives in antimicrobial research and development in Europe. BEAM recommends bold incentives that warrant action by policymakers to stimulate much needed innovation.